Patriots' Julian Edelman to Miss Entire 2017 Season

Thursday, October 5, 2017

Patriots' Julian Edelman to Miss Entire 2017 Season

A former assistant professor of urology at Tufts University and the New England Medical Center, Erol Onel is vice president of Heron Therapeutics, a California-based drug development company. Beyond his professional responsibilities, Erol Onel is an avid fan of the National Football League's (NFL) New England Patriots.

The Patriots are attempting to win their third Super Bowl in four seasons, but the team will have to do so without the services of Julian Edelman. A seventh-round selection of the Patriots in the 2009 NFL Draft, Edelman has played his entire eight-year career with the Patriots and led the team in receiving yards in two of the past four seasons. However, the 31-year-old wide receiver suffered a torn ACL in a non-contact play during a preseason game against the Detroit Lions and the Patriots later confirmed he would be out for the entire 2017 season.

Edelman recorded a career-best 1,106 receiving yards in 2016 and signed a two-year, $11 million contract with New England in the offseason. Throughout 103 career games, the California native has 4,540 receiving yards and 24 touchdowns.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

About Erol Onel

A physician in New Jersey focused on pharmaceutical development, Erol Onel, MD, most recently served Pacira Pharmaceuticals, Inc., as vice president of clinical research and medical information. In these roles, Dr. Erol Onel’s responsibilities included overseeing studies presented to the US Food and Drug Administration and engaging with Pacira’s regulatory department to ensure the completion and transmission of regulatory documentation. Among his accomplishments at Pacira, he guided the launch and approval of the firm’s major product, a non-opioid pain medication.

Over the course of his career, Dr. Onel has led held leadership roles in all areas of clinical development. With particular experience in male fertility, he played an integral role in the development of degarelix (Firmagon), a drug used in the treatment of prostate cancer.

Dr. Erol Onel earned his doctor of medicine at Yeshiva University’s Albert Einstein College of Medicine and completed a residency in urology at the University of Connecticut Health Center. Subsequently, he fulfilled the obligations of a research fellowship in andrology and sexual dysfunction at the University of Illinois at Chicago.